Regenicin, Inc.
company.status.inactiveCIK 1412659fmd_0ZTH6ZEMGE65ANGEC6GZYZCZR2Manufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Oct 01, 2007 to Mar 31, 2023, 54 periods
Latest annual · FY2021
Millions- Operating income
- (1)
- Net income
- (1)
Latest quarter · Q2 FY2023
Millions- Net income
- (0)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2016 to FY2021
- n/m
Regenicin, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2021 | FY2020 | Change | Source |
|---|---|---|---|---|
| Operating income | -$635,864 | -$510,816 | 10-K/A 2022-02-08 · proof | |
| Net income | -$639,262 | -$670,602 | 10-K 2023-01-13 · proof | |
| Cash from operating activities | -$27,291 | -$24,107 | 10-K 2023-01-13 · proof | |
| Total assets | $15,493 | $4,609 | +236.1% | 10-K 2023-01-13 · proof |
| Total liabilities | $5.6 million | $5 million | +13.1% | 10-K 2023-01-13 · proof |
| Cash and cash equivalents | $1,859 | $1,366 | +36.1% | 10-Q 2023-05-15 · proof |
- What was Regenicin, Inc.'s operating income in fiscal 2021?
- Regenicin, Inc. reported operating income of -$635,864 for fiscal 2021 (the year ended Sep 30, 2021), against -$510,816 the year before. Source: the 10-K/A filed with the SEC on Feb 8, 2022 (restated). SEC
- What was Regenicin, Inc.'s net income in fiscal 2021?
- Regenicin, Inc. reported net income of -$639,262 for fiscal 2021 (the year ended Sep 30, 2021), against -$670,602 the year before. Source: the 10-K filed with the SEC on Jan 13, 2023 (restated). SEC
- What was Regenicin, Inc.'s cash from operating activities in fiscal 2021?
- Regenicin, Inc. reported cash from operating activities of -$27,291 for fiscal 2021 (the year ended Sep 30, 2021), against -$24,107 the year before. Source: the 10-K filed with the SEC on Jan 13, 2023 (restated). SEC
- What are Regenicin, Inc.'s total assets?
- As of Sep 30, 2021, Regenicin, Inc. reported total assets of $15,493, against $4,609 a year earlier (+236.1%). Source: the 10-K filed with the SEC on Jan 13, 2023 (restated). SEC
- What are Regenicin, Inc.'s total liabilities?
- As of Sep 30, 2021, Regenicin, Inc. reported total liabilities of $5.6 million, against $5 million a year earlier (+13.1%). Source: the 10-K filed with the SEC on Jan 13, 2023 (restated). SEC
- What are Regenicin, Inc.'s cash and cash equivalents?
- As of Sep 30, 2021, Regenicin, Inc. reported cash and cash equivalents of $1,859, against $1,366 a year earlier (+36.1%). Source: the 10-Q filed with the SEC on May 15, 2023 (restated). SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1412659&period_type=annual&limit=5"Information only, not investment advice.